| Title | Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection |
| Publication Type | Journal Article |
| Year of Publication | 2012 |
| Authors | Parlane, N. A., Compton B. J., Hayman C. M., Painter G. F., Basaraba R. J., Heiser A., and Buddle B. M. |
| IRL Team | Carbohydrate Chemistry |
| Journal | Vaccine |
| Volume | 30 |
| Pagination | 580-588 |
| ISSN | 0264410X |
| Abstract | Mycobacterium bovis infects a wide range of hosts, including domestic livestock, wildlife, and humans. Development of an effective vaccine protecting against bovine tuberculosis would provide a cost-effective tuberculosis control strategy. The objective of this study was to investigate the ability of phosphatidylinositol di-mannoside (PIM2) and its derivatives to modulate cell-mediated immunity in vivo in a bovine tuberculosis mouse model in response to a relevant antigen, namely a fusion protein of mycobacterial proteins Ag85A and ESAT-6. The addition of synthetic PIM2 to the vaccine resulted in a significant reduction in lung bacterial counts and a cytokine profile indicating a Th 1 type immune response. The addition of the other PIM2 derivatives to the vaccine or the fusion protein alone did not result in reduced lung bacterial counts; moreover, the addition of PIM2ME appeared to negate the induction of an antigen-specific interferon-γ response and protection against tuberculosis. In conclusion, this study provides further evidence that PIMs can function as potent adjuvants for protein or sub-unit vaccines, but subtle structural differences among PIMs can markedly alter the type of immune response induced. © 2011 Elsevier Ltd. |
| URL | http://www.scopus.com/inward/record.url?eid=2-s2.0-84355166213&partnerID=40&md5=d96c28a54abad25850c30f337774eda4 |
| DOI | 10.1016/j.vaccine.2011.11.055 |
